T-lymphocytes

Overview

T-lymphocytes (T cells) are a critical subset of white blood cells that serve as the cornerstone of adaptive immunity. Derived from hematopoietic stem cells in the bone marrow, they mature in the thymus — an organ essential for establishing T cell diversity early in life, though it undergoes progressive involution with age. Upon maturation, T cells circulate through the blood and lymphoid organs, where they orchestrate antigen-specific immune responses. The major functional subsets include CD8+ cytotoxic T lymphocytes (CTLs), which directly kill infected or malignant cells; CD4+ helper T cells, which coordinate broader immune activity through cytokine signaling; and regulatory T cells (Tregs), which suppress excessive immune activation to prevent autoimmunity. T cell activation requires recognition of antigen-derived Peptides presented on MHC molecules by antigen-presenting cells such as dendritic cells, typically in conjunction with co-stimulatory signals mediated by receptors including CD28.

Beyond their canonical role in infectious immunity, T lymphocytes are central players in cancer immunosurveillance and are the primary target of modern immunotherapy strategies. The tumor microenvironment (TME) frequently suppresses T cell recruitment, infiltration, and effector function through mechanisms involving regulatory T cells, immunosuppressive macrophages, PD-1/PD-L1 axis signaling, and metabolic barriers. Restoring or amplifying T cell-mediated antitumor immunity — whether through checkpoint inhibitor therapies, adoptive cell transfer, cancer vaccines, or combination strategies — has become one of the most active frontiers in translational oncology. Cytokines such as IL-7 regulate T cell development, survival, and homeostasis, while key molecules including BCL-2 family proteins govern their apoptotic fate and longevity.

Focus of Latest Publications

Recent publications have focused on T-lymphocytes as key effectors and targets in cancer immunotherapy, vaccine responses, and cell-engineering strategies. Several studies examined how therapies can enhance T-cell activation, infiltration, priming, or cytotoxic differentiation in tumor settings. In advanced mucosal melanoma, combination immunotherapy was described as a way to overcome immune evasion by increasing the infiltration of tumor-specific antigen-reactive T lymphocytes. In a liver cancer vaccine study, immunization with irradiated Hepa 1-6 cells expressing GM-CSF robustly activated T cells in lymph nodes and spleen and promoted differentiation toward cytotoxic and memory phenotypes, contributing to durable protection against primary and rechallenge tumors.

Other publications investigated direct modulation of T cells during adoptive cell therapy manufacturing. One preclinical study evaluated a novel CD4-specific CAR NK cell therapy for T-cell malignancies, highlighting the challenges of autologous CAR T-cell approaches in this setting because malignant T lymphocytes share antigens with healthy T cells, creating risks of fratricide, product contamination, manufacturing limitations, and T-cell aplasia. Another study showed that venetoclax treatment during ex vivo expansion of CAR T cells targeting CD19 augmented antitumor efficacy. In that work, venetoclax reprogrammed T cells through changes in signaling and metabolic programs, including IL-2/STAT5, PI3K/AKT, oxidative phosphorylation, and glycolysis, yielding cells with improved fitness and effector function.

T-lymphocytes were also described as downstream responders in broader immunomodulatory approaches. A review of dendritic cell extracellular vesicles noted that these vesicles can transfer immunogenic molecules and co-regulatory factors to T lymphocytes in a paracrine manner, supporting immune control in cancer. Similarly, a review of hydatid cyst components reported activation of T lymphocytes alongside macrophages and natural killer cells, with modulation of Th1/Th2 balance and cytokine production. In pancreatic cancer, Kras inhibition was reported to reverse immunosuppression and enable infiltration of cytotoxic T cells, with full antitumor effects in preclinical models depending on T cells. In colorectal cancer, a nanoplatform combining cuproptosis, photodynamic therapy, and metabolic intervention was reported to enhance dendritic cell maturation and initiate T-cell priming, converting cold tumors into T cell-inflamed phenotypes and inducing durable immune memory.

T-lymphocytes were also used as a cellular context for genome-editing safety assessment. DisTAL-Seq, a TALEN-specific adaptation of DISCOVER-Seq, profiled on- and off-target sites across diverse TALENs and T cell donors, providing a platform to evaluate genome editing behavior in human T cells. Across these studies, T-lymphocytes emerged as central mediators of antitumor immunity, important readouts of vaccine and nanotherapy efficacy, and critical cells for optimizing adoptive and engineered immune therapies.

Key Publications

Mar Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies. (Cytotherapy, 2026, PMID 42139908): "The development of autologous CAR T cell approaches is challenging because of the shared antigens between the malignant T lymphocytes and healthy T cells, that can lead to fratricide, product contamination, manufacturing limitations, and T-cell aplasia."
Apr Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. (Signal transduction and targeted therapy, 2026, PMID 42036409): "T cells in particular depend heavily on BCL-2 family proteins during ontogeny and maintenance, yet the broader consequences of pharmacologically inhibiting anti-apoptotic BCL-2 proteins in T cells remain underexplored."
Apr Application of dendritic cell extracellular vesicles as a valid nanoparticle platform for cancer therapies: a narrative review. (Stem cell research & therapy, 2026, PMID 42010708): "DC EVs are valid bioshuttles to transfer immunogenic molecules, process antigens along with co-regulatory factors to other immune cell subsets like T lymphocytes, involved in the control of immune responses in a paracrine manner."
Apr Irradiated Liver Cancer Cell Vaccine Transfected With GM-CSF Induces Specific and Long-Lasting Anti-tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM-CSF. (Cell proliferation, 2026, PMID 41947668): "Hepa 1-6-mGM-CSF immunisation robustly activated dendritic cells (DCs) and T cells in both lymph nodes and spleen, characterised by enhanced DC maturation and migration, as well as the differentiation of T cells toward cytotoxic and memory phenotypes."
Apr Advanced Mucosal Melanoma Therapies: Current Status and Future Directions. (Current treatment options in oncology, 2026, PMID 41944928): "Combination immunotherapy can overcome immune evasion by enhancing the infiltration of tumor-specific antigen-reactive T lymphocytes, thereby exhibiting potentiated anti-tumor activity."
Apr DisTAL-Seq: A TALEN-specific adaptation of DISCOVER-Seq for off-target profiling. (Molecular therapy. Nucleic acids, 2026, PMID 41883584): "Using DisTAL-Seq, we identified and validated on- and off-target sites across diverse TALENs and T cell donors."
Apr Potential immunomodulatory and antitumor properties of hydatid cysts components. (International immunopharmacology, 2026, PMID 41785598): "activate immune effector cells, including macrophages, natural killer (NK) cells, and T lymphocytes."
Apr KRAS Inhibitors in Pancreas Cancer: Facts and Hopes about the Immunotherapy We Have All Been Waiting for. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 41642174): "In preclinical studies, the full antitumor effects of RAS inhibitors depend on T cells such that regressions in mice lacking T cells (or cross-presenting dendritic cells) are less deep and less durable than those in T cell-replete mice."
May Nano-purpurin-Cu delivery via TPGS-induced macropinocytosis enables cuproptosis/metabolic synergy to ablate cancer stemness and Boost immunotherapy in colorectal cancer. (Biomaterials, 2026, PMID 41330333): "Concurrently, purpurin reprograms glutamine metabolism via glutaminase inhibition, which enhances dendritic cell (DC) maturation and initiates T-cell priming."